Premium
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma
Author(s) -
Flygare Jenny,
Gustafsson Kristin,
Kimby Eva,
Christensson Birger,
Sander Birgitta
Publication year - 2005
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2005.11.020
Subject(s) - cannabinoid receptor , cannabinoid , cannabinoid receptor type 2 , agonist , mantle cell lymphoma , viability assay , receptor , chemistry , endocannabinoid system , cannabinoid receptor antagonist , pharmacology , microbiology and biotechnology , apoptosis , biology , medicine , lymphoma , biochemistry
We have earlier reported overexpression of the central and peripheral cannabinoid receptors CB1 and CB2 in mantle cell lymphoma (MCL), a B cell non‐Hodgkin lymphoma. In this study, treatment with cannabinoid receptor ligands caused a decrease in viability of MCL cells, while control cells lacking CB1 were not affected. Interestingly, equipotent doses of the CB1 antagonist SR141716A and the CB1/CB2 agonist anandamide inflicted additive negative effects on viability. Moreover, treatment with the CB1/CB2 agonist Win‐55,212‐2 caused a decrease in long‐term growth of MCL cells in culture. Induction of apoptosis, as measured by FACS/Annexin V–FITC, contributed to the growth suppressive effect of Win‐55,212‐2. Our data suggest that cannabinoid receptors may be considered as potential therapeutic targets in MCL.